Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience

Basit Öğe Kaydı
dc.contributor.authorGemici, Ali İhsan
dc.contributor.authorAydoğdu, İsmet
dc.contributor.authorTerzi, Hatice
dc.contributor.authorŞencan, Mehmet
dc.contributor.authorAslan, Alma
dc.contributor.authorKaya, Ali Hakan
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorAyyıldız, Orhan
dc.contributor.orcid0000-0001-5673-8408
dc.contributor.orcid0000-0002-3385-8359
dc.contributor.orcid0000-0003-3471-1305
dc.contributor.orcid0000-0001-9350-1485
dc.contributor.orcid0000-0002-1459-3906
dc.contributor.orcid0000-0002-5994-2735
dc.date.accessioned2024-04-24T15:59:24Z
dc.date.available2024-04-24T15:59:24Z
dc.date.issued2018
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractNodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.en_US
dc.identifier.citationGemici, A. İ., Aydoğdu, İ., Terzi, H., Şencan, M., Aslan, A., Kaya, A. H. ve diğerleri. (2018). Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience. Hematological Oncology, 36(1), 116-120.
dc.identifier.doi10.1002/hon.2460
dc.identifier.endpage120en_US
dc.identifier.issn0278-0232
dc.identifier.issn1099-1069
dc.identifier.issue1en_US
dc.identifier.pmid28707314en_US
dc.identifier.scopus2-s2.0-85023602570en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage116en_US
dc.identifier.urihttps://doi.org/10.1002/hon.2460
dc.identifier.urihttps://hdl.handle.net/11468/14043
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2460
dc.identifier.volume36en_US
dc.identifier.wosWOS:000425633300017
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAyyıldız, Orhan
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofHematological Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNodular lymphocyte predominant hodgkin's lymphomaen_US
dc.subjectOverall survivalen_US
dc.subjectProgression-free survivalen_US
dc.subjectTreatmenten_US
dc.titleNodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice.pdf
Boyut:
296.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu